一种新的癌蛋白 Pirh2：从 MDM2 的阴影中崛起。
A novel oncoprotein Pirh2: rising from the shadow of MDM2.
机构信息
School of Medicine, Wuhan University, Wuhan, China.
出版信息
Cancer Sci. 2011 May;102(5):909-17. doi: 10.1111/j.1349-7006.2011.01899.x. Epub 2011 Feb 28.
Abstract
Pirh2 (p53-induced RING-H2) is an E3 ubiquitin ligase that can target p53 for degradation and thereby repress a diverse group of biological activities regulated by p53. Notably, Pirh2, rather than MDM2, is the primary degrader of active p53 under conditions of DNA damage. Moreover, Pirh2 is highly expressed in multiple cancer cell lines regardless of p53 status. Recent research has shown that Pirh2 is involved in many signalling pathways related to the genesis and evolution of cancer. This review aims to summarize a comprehensive picture of the role of Pirh2 in cellular processes and its significance to tumorigenesis. Furthermore, this review focuses on its potential role as a cancer therapeutic target.
摘要
Pirh2（p53 诱导的 RING-H2）是一种 E3 泛素连接酶，可将 p53 作为靶标进行降解，从而抑制由 p53 调节的多种生物活性。值得注意的是，在 DNA 损伤的情况下，Pirh2 而不是 MDM2，是活性 p53 的主要降解物。此外，Pirh2 在多种癌细胞系中无论 p53 状态如何都高度表达。最近的研究表明，Pirh2 参与了与癌症发生和演变相关的许多信号通路。本综述旨在总结 Pirh2 在细胞过程中的作用及其对肿瘤发生的意义的综合情况。此外，本综述还重点介绍了其作为癌症治疗靶点的潜在作用。
相似文献
1
A novel oncoprotein Pirh2: rising from the shadow of MDM2.一种新的癌蛋白 Pirh2：从 MDM2 的阴影中崛起。
Cancer Sci. 2011 May;102(5):909-17. doi: 10.1111/j.1349-7006.2011.01899.x. Epub 2011 Feb 28.
2
Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.两种 p53 E3 连接酶 Mdm2 和 Pirh2 的 RING 结构域的结构与功能比较。
J Biol Chem. 2011 Feb 11;286(6):4796-808. doi: 10.1074/jbc.M110.157669. Epub 2010 Nov 17.
3
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.人类癌细胞DNA损伤后p53泛素蛋白连接酶Pirh2和MdM2之间的差异反应。
Exp Cell Res. 2006 Oct 15;312(17):3370-8. doi: 10.1016/j.yexcr.2006.07.005. Epub 2006 Jul 21.
4
Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.MDM2、MDMX、Pirh2 和 COP1：p53 的负调控因子相互作用。
Mol Biol Rep. 2011 Jan;38(1):229-36. doi: 10.1007/s11033-010-0099-x. Epub 2010 Mar 24.
5
Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.鉴定和表征Pirh2泛素连接酶的两种新型同工型，它们独立于RING指结构域对p53进行负调控。
J Biol Chem. 2009 Aug 14;284(33):21955-21970. doi: 10.1074/jbc.M109.024232. Epub 2009 May 29.
6
A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination.新鉴定的 Pirh2 底物 SCYL1-BP1 可与 MDM2 结合并加速 MDM2 自身泛素化。
FEBS Lett. 2010 Aug 4;584(15):3275-8. doi: 10.1016/j.febslet.2010.06.027. Epub 2010 Jun 23.
7
p53 ubiquitination: Mdm2 and beyond.p53泛素化：Mdm2及其他相关蛋白
Mol Cell. 2006 Feb 3;21(3):307-15. doi: 10.1016/j.molcel.2006.01.020.
8
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.Pirh2 RING-finger E3 泛素连接酶：在肿瘤发生和癌症治疗中的作用。
FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.
9
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.肝再生磷酸酶 3 通过 MDM2 和 PIRH2 下调 p53。
Life Sci. 2010 Jan 2;86(1-2):66-72. doi: 10.1016/j.lfs.2009.11.010. Epub 2009 Nov 27.
10
The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.p53的囚车：发现COP1、Pirh2和MDM2可抵抗细胞凋亡和生长停滞。
Cancer Biol Ther. 2004 Aug;3(8):721-5. doi: 10.4161/cbt.3.8.1068. Epub 2004 Aug 1.
引用本文的文献
1
Recognition of an Ala-rich C-degron by the E3 ligase Pirh2.富含丙氨酸的 C 端降解基序被 E3 连接酶 Pirh2 识别。
Nat Commun. 2023 Apr 29;14(1):2474. doi: 10.1038/s41467-023-38173-6.
2
The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.E3泛素连接酶在卵巢癌化疗耐药中的新作用
Cancer Drug Resist. 2021 Jun 19;4(2):365-381. doi: 10.20517/cdr.2020.115. eCollection 2021.
3
Mechanism and Disease Association With a Ubiquitin Conjugating E2 Enzyme: UBE2L3.泛素连接酶 E2 酶 UBE2L3 的作用机制及与疾病的关联
Front Immunol. 2022 Feb 21;13:793610. doi: 10.3389/fimmu.2022.793610. eCollection 2022.
4
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.E3泛素连接酶Pirh2增强人非小细胞肺癌细胞的致瘤特性。
Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.
5
Molecular Analysis of the HOXA2-Dependent Degradation of RCHY1.HOXA2 依赖的 RCHY1 降解的分子分析
PLoS One. 2015 Oct 23;10(10):e0141347. doi: 10.1371/journal.pone.0141347. eCollection 2015.
6
Human Pirh2 is a novel inhibitor of prototype foamy virus replication.人类Pirh2是一种新型的泡沫病毒原型复制抑制剂。
Viruses. 2015 Apr 2;7(4):1668-84. doi: 10.3390/v7041668.
7
The MDM2-p53 pathway revisited.重新审视MDM2-p53信号通路。
J Biomed Res. 2013 Jul;27(4):254-71. doi: 10.7555/JBR.27.20130030. Epub 2013 Jun 6.
8
WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.WWP1 E3 连接酶将 LATS1 作为泛素化介导的乳腺癌细胞降解的靶标。
PLoS One. 2013;8(4):e61027. doi: 10.1371/journal.pone.0061027. Epub 2013 Apr 3.
9
Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.天然产物 MDM2 抑制剂：抗癌活性及作用机制。
Curr Med Chem. 2012;19(33):5705-25. doi: 10.2174/092986712803988910.
10
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.p73 肿瘤抑制因子被 Pirh2 RING 指结构域 E3 泛素连接酶靶向，用于蛋白酶体依赖性降解。
J Biol Chem. 2011 Oct 14;286(41):35388-35395. doi: 10.1074/jbc.M111.261537. Epub 2011 Aug 18.
本文引用的文献
1
Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.基于单核苷酸多态性微阵列比较基因组杂交分析鉴定的人乳腺癌中雌激素受体（ER）阳性和 ER 阴性之间的基因组差异。
Cancer. 2011 May 15;117(10):2024-34. doi: 10.1002/cncr.25770. Epub 2010 Nov 29.
2
A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination.新鉴定的 Pirh2 底物 SCYL1-BP1 可与 MDM2 结合并加速 MDM2 自身泛素化。
FEBS Lett. 2010 Aug 4;584(15):3275-8. doi: 10.1016/j.febslet.2010.06.027. Epub 2010 Jun 23.
3
Regulation of p53 in embryonic stem cells.胚胎干细胞中 p53 的调控。
Exp Cell Res. 2010 Sep 10;316(15):2434-46. doi: 10.1016/j.yexcr.2010.06.006. Epub 2010 Jun 11.
4
p53-family proteins and their regulators: hubs and spokes in tumor suppression.p53 家族蛋白及其调控因子：肿瘤抑制中的枢纽和辐条。
Cell Death Differ. 2010 Jun;17(6):901-11. doi: 10.1038/cdd.2010.35. Epub 2010 Apr 9.
5
Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.MDM2、MDMX、Pirh2 和 COP1：p53 的负调控因子相互作用。
Mol Biol Rep. 2011 Jan;38(1):229-36. doi: 10.1007/s11033-010-0099-x. Epub 2010 Mar 24.
6
Immunity, inflammation, and cancer.免疫、炎症与癌症。
Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025.
7
Cancer and inflammation: implications for pharmacology and therapeutics.癌症与炎症：对药理学和治疗学的影响。
Clin Pharmacol Ther. 2010 Apr;87(4):401-6. doi: 10.1038/clpt.2009.312. Epub 2010 Mar 3.
8
Systems survey of endocytosis by multiparametric image analysis.多参数图像分析的胞吞作用系统调查。
Nature. 2010 Mar 11;464(7286):243-9. doi: 10.1038/nature08779. Epub 2010 Feb 28.
9
Bi-directional SIFT predicts a subset of activating mutations.双向 SIFT 预测了一组激活突变。
PLoS One. 2009 Dec 14;4(12):e8311. doi: 10.1371/journal.pone.0008311.
10
Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation.Pirh2 E3 泛素连接酶将 DNA 聚合酶 eta 靶向 20S 蛋白酶体降解。
Mol Cell Biol. 2010 Feb;30(4):1041-8. doi: 10.1128/MCB.01198-09. Epub 2009 Dec 14.
Zotero 插件